Results 261 to 270 of about 100,944 (279)

Tocilizumab in COVID‐19 pneumonia: Practical proposals based on a narrative review of randomised trials

Reviews in Medical Virology, 2022
Timothee Klopfenstein, Vincent Gendrin, Souheil Zayet   +2 more
exaly  

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

Frontiers of Medicine, 2021
Dongsheng Wang, Binqing Fu, Dongliang Yang   +2 more
exaly  

Tocilizumab

Reactions Weekly, 2015
  +4 more sources

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Lancet, The, 2016
Dinesh Khanna, Christopher P Denton, Angelika Jahreis   +2 more
exaly  

Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review

Seminars in Arthritis and Rheumatism, 2020
Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi   +2 more
exaly  

Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients

Journal of Autoimmunity, 2018
Arsene Mékinian, Alessandra Soriano, Isabelle Koné-Paut   +2 more
exaly  

Tocilizumab

Reactions Weekly, 2017
  +4 more sources

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Lancet, The, 2013
Cem Gabay, Paul Emery, Rieke Alten
exaly  

Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

Infectious Diseases and Therapy, 2020
Aranzazu Sancho-Lopez, Ferrán Torres, Víctor Moreno-Torres   +2 more
exaly  

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Blood, 2008
Norihiro Nishimoto, Kimio Terao, Toru Mima   +2 more
exaly